MXPA01000830A - Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina. - Google Patents

Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina.

Info

Publication number
MXPA01000830A
MXPA01000830A MXPA01000830A MXPA01000830A MXPA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A MX PA01000830 A MXPA01000830 A MX PA01000830A
Authority
MX
Mexico
Prior art keywords
gene
expression
vector
cells
polynucleotide
Prior art date
Application number
MXPA01000830A
Other languages
English (en)
Spanish (es)
Inventor
Michael Antoniou
Original Assignee
Cobra Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815879.3A external-priority patent/GB9815879D0/en
Priority claimed from GBGB9906712.6A external-priority patent/GB9906712D0/en
Priority claimed from GBGB9909494.8A external-priority patent/GB9909494D0/en
Application filed by Cobra Therapeutics Ltd filed Critical Cobra Therapeutics Ltd
Publication of MXPA01000830A publication Critical patent/MXPA01000830A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/20Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/46Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/80Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85Vector systems having a special element relevant for transcription from vertebrates mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MXPA01000830A 1998-07-21 1999-07-21 Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina. MXPA01000830A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9815879.3A GB9815879D0 (en) 1998-07-21 1998-07-21 A polynucleotide
US10768898P 1998-11-09 1998-11-09
GBGB9906712.6A GB9906712D0 (en) 1999-03-23 1999-03-23 A polynucleotide
US12741099P 1999-04-01 1999-04-01
GBGB9909494.8A GB9909494D0 (en) 1999-04-23 1999-04-23 A plasmid
US13401699P 1999-05-12 1999-05-12
PCT/GB1999/002357 WO2000005393A2 (en) 1998-07-21 1999-07-21 A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)

Publications (1)

Publication Number Publication Date
MXPA01000830A true MXPA01000830A (es) 2002-06-04

Family

ID=27547316

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01000830A MXPA01000830A (es) 1998-07-21 1999-07-21 Un polinucleotido que comprende un elemento de abertura ubiculo de cromatina.

Country Status (8)

Country Link
EP (2) EP2348118A1 (enExample)
JP (4) JP4220673B2 (enExample)
KR (3) KR100795626B1 (enExample)
CN (1) CN100365127C (enExample)
AU (1) AU771111B2 (enExample)
CA (1) CA2333852C (enExample)
MX (1) MXPA01000830A (enExample)
WO (1) WO2000005393A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5051738B2 (ja) * 2000-09-20 2012-10-17 イー・エム・デイー・ミリポア・コーポレイシヨン 人工遍在的クロマチン開放エレメント(ucoe)
CA2435972C (en) 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
ES2387951T3 (es) * 2001-04-05 2012-10-04 Emd Millipore Corporation Expresión génica mejorada
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
CA2443275C (en) * 2001-04-05 2013-02-05 Ml Laboratories Plc Improved gene expression
WO2002097059A2 (en) 2001-05-30 2002-12-05 Chromos Molecular Systems, Inc. Chromosome-based platforms
EP1402006A4 (en) * 2001-06-04 2005-11-23 Ml Lab Plc COMPOSITIONS AND METHODS FOR LARGE SCALE PRODUCTION AND HIGH EFFICIENCY OF RECOMBINANT PROTEINS
ATE466943T1 (de) 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor aktivität
WO2003056912A2 (en) 2002-01-09 2003-07-17 Minos Biosystems Limited Inducible transposition in transgenic organism using transposon vector
WO2003106674A2 (en) 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
AU2003238719B2 (en) 2002-06-14 2008-02-21 Chromagenics B.V. A method for simultaneous production of multiple proteins, vectors and cells for use therein
ES2373549T3 (es) 2002-12-18 2012-02-06 Chromagenics B.V. Método para mejorar la producción de proteínas.
WO2004056986A2 (en) * 2002-12-20 2004-07-08 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
EP2267140A1 (en) 2003-02-01 2010-12-29 Millipore Corporation Improved genetic elements providing high levels of expression
RU2375450C2 (ru) 2003-10-24 2009-12-10 Селексис С.А. Днк, повышающая продуцирование белка, и ее применение
US8354251B2 (en) 2003-12-31 2013-01-15 Kalobios Pharmaceuticals, Inc. Transactivation system for mammalian cells
WO2006007850A1 (en) 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060172382A1 (en) 2004-11-08 2006-08-03 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
AU2005300503B2 (en) 2004-11-08 2010-12-16 Chromagenics B.V. Selection of host cells expressing protein at high levels
GB0504587D0 (en) 2005-03-05 2005-04-13 Ml Lab Plc Vectors comprising guinea pig CMV regulatory elements
GB0509965D0 (en) 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
WO2007107578A1 (en) 2006-03-20 2007-09-27 Chromagenics B.V. Expression augmenting dna fragments, use thereof, and methods for finding thereof
JP2010525789A (ja) * 2007-01-08 2010-07-29 ミリポア・コーポレイション 1つ又はそれ以上のきょう雑物の低下したレベルの存在下で組換えタンパク質を生産するための細胞培養法
CN104531699B (zh) * 2014-10-09 2017-03-15 河南农业大学 一种增强外源基因表达的猪的ucoe调控元件片段
CA2965849A1 (en) * 2014-12-16 2016-06-23 Garvan Institute Of Medical Research Sequencing controls
WO2018175153A1 (en) 2017-03-19 2018-09-27 Applied Stemcell, Inc. Novel integration sites and uses thereof
WO2018187156A1 (en) 2017-04-03 2018-10-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for multiplexed quantitative analysis of cell lineages
EP3720958A1 (en) * 2017-12-07 2020-10-14 Integrity Biosolutions, LLC Engineered ubiquitous chromatin opening elements and uses thereof
US11781146B2 (en) * 2018-05-24 2023-10-10 National University Corporation Hokkaido University Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element
EP3837381A1 (en) * 2018-08-15 2021-06-23 Illumina, Inc. Compositions and methods for improving library enrichment
JP2022502063A (ja) * 2018-10-02 2022-01-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 細胞系列の多重定量分析のための組成物および方法
US20220193266A1 (en) * 2019-04-30 2022-06-23 Chan Zuckerberg Biohub, Inc. A novel chromatin-opening element for stable long term gene expression
CN112575031B (zh) * 2019-09-29 2023-04-07 新乡医学院 一种遍在染色质开放表达元件、重组表达载体、表达系统及其制备方法、应用
CN116574735B (zh) * 2023-07-03 2023-11-10 艾米能斯(苏州)生物科技有限公司 一种多核苷酸及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
GB8718779D0 (en) 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
EP0945515A3 (en) 1989-11-06 2002-08-21 Cell Genesys, Inc. Production of proteins using homologous recombination
DK0532525T3 (da) 1990-05-18 1995-12-04 Genentech Inc Nye protein-polykationkonjugater
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
GB9109928D0 (en) 1991-05-08 1991-07-03 Interox Chemicals Ltd Thickened compositions
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP0632722A4 (en) 1992-03-20 1997-07-30 Baylor College Medicine DNA TRANSPORTATION SYSTEM AND INSTRUCTIONS FOR USE.
US5583009A (en) 1992-12-08 1996-12-10 University Of Washington Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
JP2002514892A (ja) 1995-06-08 2002-05-21 コブラ セラピューティクス リミテッド 遺伝子治療における合成ウイルス様粒子の使用
WO1998007876A2 (en) 1996-08-16 1998-02-26 Medical Research Council Self-replicating episomal expression vectors conferring tissue-specific gene expression
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
JP2001512312A (ja) 1997-02-12 2001-08-21 コブラ セラピューティクス リミテッド 高効率トランスフェクションに関する組成物および方法

Also Published As

Publication number Publication date
WO2000005393A2 (en) 2000-02-03
KR20070108336A (ko) 2007-11-09
EP1098986B1 (en) 2011-12-28
KR100795626B1 (ko) 2008-01-17
CN1334878A (zh) 2002-02-06
AU5053499A (en) 2000-02-14
JP2005052149A (ja) 2005-03-03
CA2333852C (en) 2007-05-29
EP1098986A2 (en) 2001-05-16
JP2008109931A (ja) 2008-05-15
HK1035740A1 (en) 2001-12-07
JP2009102331A (ja) 2009-05-14
CA2333852A1 (en) 2000-02-03
CN100365127C (zh) 2008-01-30
EP2348118A1 (en) 2011-07-27
JP4220673B2 (ja) 2009-02-04
KR20010083131A (ko) 2001-08-31
JP2002522027A (ja) 2002-07-23
AU771111B2 (en) 2004-03-11
WO2000005393A3 (en) 2000-08-17
KR20090117675A (ko) 2009-11-12

Similar Documents

Publication Publication Date Title
CA2333852C (en) A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
US6689606B2 (en) Polynucleotide
CN1461343B (zh) 多核苷酸
US20040019923A1 (en) Exogenous proteins expressed in avians and their eggs
US20060171921A1 (en) Glycosylated interferon
US6949361B2 (en) Polynucleotide
CN101260384A (zh) 具有遍在染色质开放表达元件(ucoe)的聚核苷酸
HK1035740B (en) A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
Miyazaki Basic components of gene expression plasmids

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EMD MILLIPORE CORPORATION

GB Transfer or rights

Owner name: EMD MILLIPORE CORPORATION

HC Change of company name or juridical status

Owner name: EMD MILLIPORE CORPORATION

GB Transfer or rights

Owner name: EMD MILLIPORE CORPORATION

FG Grant or registration
HC Change of company name or juridical status

Owner name: EMD MILLIPORE CORPORATION

MM Annulment or lapse due to non-payment of fees